Featured Research

from universities, journals, and other organizations

HIV treatment reduces risk of malaria recurrence in children

Date:
November 28, 2012
Source:
NIH/National Institute of Child Health and Human Development
Summary:
A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers.

A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health.

Related Articles


The combination of protease inhibitors lopinavir and ritonavir contributed to an overall reduction of 40 percent in the rate of malaria among a group of HIV-positive infants and children up to 6 years old in Uganda who were also being treated with anti-malarial drugs. This reduction was in comparison to malaria incidence among children receiving a drug treatment of one of a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Protease inhibitors interfere with the reproduction of HIV by blocking the protease enzyme of HIV. The protease inhibitor combination used in the study did not appear to inhibit an initial bout of malaria--but reduce the chances of a recurrence of the disease following a successful treatment.

The researchers found that blood levels of anti-malarial drugs were higher in children who had received the protease inhibitors, which may help explain their effectiveness at preventing malaria's return.

"It's possible that these protease inhibitors prevent antimalarial drugs from breaking down or have some other additive effect against the malarial parasite," said Lynne Mofenson, M.D., chief of the Pediatric, Adolescent, and Maternal AIDS Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH institute that funded the study. "Laboratory studies also suggest that protease inhibitors can block the malaria parasite outright. Finding out why this drug combination is effective is an area for further study."

Previous studies have shown that the lopinavir-ritonavir combination also is more effective for treating HIV-positive infants than widely used treatment regimens based on the medication nevirapine.

The NNRTI nevirapine is the first-line treatment for HIV recommended by the World Health Organization for children in developing countries. It is less expensive than the protease inhibitor combination and, unlike the protease inhibitors, does not need refrigeration. Compared to nevirapine, the liquid formulation of the protease inhibitor combination is also unpleasant tasting. However, recent changes in the protease inhibitor formulation may overcome these barriers to expanding its use in resource poor settings, Dr. Mofenson said.

"New formulations have been developed for the drug so that it can be sprinkled on food, tastes better, and doesn't need refrigeration," she said. "This may help where it is needed most."

First author Jane Achan, MMed, of Makerere University and the Infectious Diseases Research Collaboration, in Uganda, collaborated with colleagues in Uganda and at the University of California, San Francisco.

Their findings appear in the New England Journal of Medicine.

More than 170 HIV-positive infants and children participated in the study. They received either an NNRTI (nevirapine for children under age 3, efavirenz for children over age 3) or the protease inhibitor-based treatment. In addition, the children received insecticide-treated nets to keep mosquitoes away while they slept, vitamins, a clean source of water, and medication to prevent infection with the malaria parasite, which is transmitted by mosquitoes.

Even with these measures, the researchers found that the children's risk of developing malaria in the first six months of their anti HIV treatment was greater than 40 percent. Although the risk was slightly higher in the nevirapine-treated group, the difference was not significant statistically.

However, of the children who developed malaria and were successfully treated for it during the study, 41 percent of those taking an NNRTI developed another case of malaria within 28 days of clearing their system of the parasite the first time. In contrast, only 14 percent of those on the combination lopinavir-ritonavir treatment developed another case of malaria within this time period.

When comparing the two groups over a 63-day period, the researchers found that 54 percent of the NNRTI group had a recurrence of malaria, compared with 28 percent of the group taking the lopinavir-ritonavir treatment.

In addition, tests conducted one week after the start of malaria treatment showed that blood levels of an anti-malaria drug were higher among children receiving the protease inhibitor combination than among their counterparts taking the nevirapine-based treatment.

"The finding that this protease inhibitor combination not only appears more effective at treating HIV than NNRTIs, but also protects against malaria recurrence, merits its consideration for children living in areas where malaria is rampant," Dr. Mofenson said.


Story Source:

The above story is based on materials provided by NIH/National Institute of Child Health and Human Development. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jane Achan, Abel Kakuru, Gloria Ikilezi, Theodore Ruel, Tamara D. Clark, Christian Nsanzabana, Edwin Charlebois, Francesca Aweeka, Grant Dorsey, Philip J. Rosenthal, Diane Havlir, Moses R. Kamya. Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children. New England Journal of Medicine, 2012; 367 (22): 2110 DOI: 10.1056/NEJMoa1200501

Cite This Page:

NIH/National Institute of Child Health and Human Development. "HIV treatment reduces risk of malaria recurrence in children." ScienceDaily. ScienceDaily, 28 November 2012. <www.sciencedaily.com/releases/2012/11/121128182951.htm>.
NIH/National Institute of Child Health and Human Development. (2012, November 28). HIV treatment reduces risk of malaria recurrence in children. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2012/11/121128182951.htm
NIH/National Institute of Child Health and Human Development. "HIV treatment reduces risk of malaria recurrence in children." ScienceDaily. www.sciencedaily.com/releases/2012/11/121128182951.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins